December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ:SILO)

0.5876 -0.0145 (-2.41%)
Streaming Delayed Price Updated: 2:40 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 188,479
Open 0.5805
Bid (Size) 0.5853 (6)
Ask (Size) 0.5898 (1)
Prev. Close 0.6021
Today's Range 0.5805 - 0.5978
52wk Range 0.4101 - 3.370
Shares Outstanding 98,671,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company’s Commitment to Multi-Chain Growth
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
From Silo Pharma, Inc.
Via GlobeNewswire

Performance

YTD
-38.1%
-38.1%
1 Month
-19.1%
-19.1%
3 Month
-7.0%
-7.0%
6 Month
-45.3%
-45.3%
1 Year
-49.8%
-49.8%

More News

Read More
Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
From Silo Pharma, Inc.
Via GlobeNewswire
These stocks are gapping in today's session
Via Chartmill
Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
From Silo Pharma, Inc.
Via GlobeNewswire
EXCLUSIVE: Silo Pharma Partners With Fireblocks To Advance Crypto Treasury Strategy Acquisition And Security
Via Benzinga
These stocks are moving in today's pre-market session
Via Chartmill
Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
From Silo Pharma, Inc.
Via GlobeNewswire
3 Under-the-Radar Biotechs Under $5 That Could Soar 200%
Via MarketBeat
Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
From Silo Pharma, Inc.
Via GlobeNewswire
EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers
Via Benzinga
Silo Pharma’s Alzheimer’s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
From Silo Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expects SPC-15 PTSD Study Results Within 90 Days
Via Investor Brand Network
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Via Get News
Topics Intellectual Property
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Via Press Release Distribution Service
Topics Intellectual Property

Frequently Asked Questions

Is Silo Pharma, Inc. - Common Stock publicly traded?
Yes, Silo Pharma, Inc. - Common Stock is publicly traded.
What exchange does Silo Pharma, Inc. - Common Stock trade on?
Silo Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Silo Pharma, Inc. - Common Stock?
The ticker symbol for Silo Pharma, Inc. - Common Stock is SILO on the Nasdaq Stock Market
What is the current price of Silo Pharma, Inc. - Common Stock?
The current price of Silo Pharma, Inc. - Common Stock is 0.5876
When was Silo Pharma, Inc. - Common Stock last traded?
The last trade of Silo Pharma, Inc. - Common Stock was at 10/17/25 02:40 PM ET
What is the market capitalization of Silo Pharma, Inc. - Common Stock?
The market capitalization of Silo Pharma, Inc. - Common Stock is 57.98M
How many shares of Silo Pharma, Inc. - Common Stock are outstanding?
Silo Pharma, Inc. - Common Stock has 58M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.